{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:54:41Z","timestamp":1791906881768,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T00:00:00Z","timestamp":1426809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T00:00:00Z","timestamp":1426809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal impairment (RI) is seen in over a quarter of patients with newly diagnosed multiple myeloma (NDMM). It is not clear if reversal of RI improves the outcome to that expected for NDMM patients without RI. We evaluated 1135 consecutive patients with NDMM seen at the Mayo Clinic between January 2003 and December 2012. RI was defined as having a creatinine clearance (CrCl) &lt;40ml\/min. The median overall survival (OS) for patients with RI at diagnosis receiving and not receiving novel agent induction therapy was not reached vs 46 months (<jats:italic>P<\/jats:italic>&lt;0.001). The median OS for patients with CrCl \u2a7e40\u2009ml\/min at diagnosis, CrCl &lt;40\u2009ml\/min at diagnosis but improved to \u2a7e40\u2009ml\/min and CrCl &lt;40\u2009ml\/min at diagnosis and remained &lt;40\u2009ml\/min, were 112, 56 and 33 months, respectively (<jats:italic>P<\/jats:italic>&lt;0.001). The complete renal response rate for patients with RI at diagnosis receiving novel agent induction therapy compared to the rest was 40 vs 16% (<jats:italic>P<\/jats:italic>&lt;0.001). In conclusion, patients with reversal of RI have improved outcomes, but it remains inferior to patients with normal renal function at diagnosis. These results have implications for identifying early treatment strategies for patients at risk of developing renal insufficiency.<\/jats:p>","DOI":"10.1038\/bcj.2015.20","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T17:04:30Z","timestamp":1426871070000},"page":"e296-e296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"5","author":[{"given":"W I","family":"Gonsalves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S V","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Q","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S R","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F K","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R S","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S J","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Lust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Zeldenrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S K","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,20]]},"reference":[{"key":"BFbcj201520_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"BFbcj201520_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21\u201333.","journal-title":"Mayo Clin Proc"},{"key":"BFbcj201520_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","volume":"53","author":"LM Knudsen","year":"1994","unstructured":"Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J . Renal function in newly diagnosed multiple myeloma\u2014a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207\u2013212.","journal-title":"Eur J Haematol"},{"key":"BFbcj201520_CR4","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV . Multiple myeloma. N Engl J Med 2004; 351: 1860\u20131873.","journal-title":"N Engl J Med"},{"key":"BFbcj201520_CR5","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1001\/archinte.1990.00040031693017","volume":"150","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Dixon D . Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693\u20131695.","journal-title":"Arch Intern Med"},{"key":"BFbcj201520_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrneph.2011.168","volume":"8","author":"CA Hutchison","year":"2012","unstructured":"Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2012; 8: 43\u201351.","journal-title":"Nat Rev Nephrol"},{"key":"BFbcj201520_CR7","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blade","year":"1998","unstructured":"Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889\u20131893.","journal-title":"Arch Intern Med"},{"key":"BFbcj201520_CR8","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1365-2141.1995.tb05400.x","volume":"91","author":"R Torra","year":"1995","unstructured":"Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854\u2013859.","journal-title":"Br J Haematol"},{"key":"BFbcj201520_CR9","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219\u20139226.","journal-title":"J Clin Oncol"},{"key":"BFbcj201520_CR10","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1038\/bcj.2011.34","volume":"1","author":"M Kleber","year":"2011","unstructured":"Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wasch R et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 2011; 1: e35.","journal-title":"Blood Cancer J"},{"key":"BFbcj201520_CR11","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976\u20134984.","journal-title":"J Clin Oncol"},{"key":"BFbcj201520_CR12","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516\u20132520.","journal-title":"Blood"},{"key":"BFbcj201520_CR13","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122\u20131128.","journal-title":"Leukemia"},{"key":"BFbcj201520_CR14","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521\u20132526.","journal-title":"Blood"},{"key":"BFbcj201520_CR15","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1038\/bcj.2013.38","volume":"3","author":"AA Chanan-Khan","year":"2013","unstructured":"Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J 2013; 3: e143.","journal-title":"Blood Cancer J"},{"key":"BFbcj201520_CR16","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1038\/bcj.2014.77","volume":"4","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y et al. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Cancer J 2014; 4: e257.","journal-title":"Blood Cancer J"},{"key":"BFbcj201520_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","volume":"25","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 2014; 25: 195\u2013200.","journal-title":"Ann Oncol"},{"key":"BFbcj201520_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/leu.2012.182","volume":"27","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 2013; 27: 423\u2013429.","journal-title":"Leukemia"},{"key":"BFbcj201520_CR19","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3109\/10428194.2011.597906","volume":"52","author":"E Eleftherakis-Papapiakovou","year":"2011","unstructured":"Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, Gkotzamanidou M, Grapsa I, Psimenou E et al. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leuk Lymphoma 2011; 52: 2299\u20132303.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201520_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","volume":"65","author":"LM Knudsen","year":"2000","unstructured":"Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175\u2013181.","journal-title":"Eur J Haematol"},{"key":"BFbcj201520_CR21","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412\u20133420.","journal-title":"J Clin Oncol"},{"key":"BFbcj201520_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4065\/mcp.2009.0677","volume":"85","author":"P Kapoor","year":"2010","unstructured":"Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc 2010; 85: 532\u2013537.","journal-title":"Mayo Clin Proc"},{"key":"BFbcj201520_CR23","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1038\/bcj.2012.37","volume":"2","author":"A Kalff","year":"2012","unstructured":"Kalff A, Spencer A . The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J 2012; 2: e89.","journal-title":"Blood Cancer J"},{"key":"BFbcj201520_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461\u2013470.","journal-title":"Ann Intern Med"},{"key":"BFbcj201520_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV . Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3\u20139.","journal-title":"Leukemia"},{"key":"BFbcj201520_CR26","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538\u2013e548.","journal-title":"Lancet Oncol"},{"key":"BFbcj201520_CR27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.leukres.2010.04.024","volume":"34","author":"M Roussou","year":"2010","unstructured":"Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010; 34: 1395\u20131397.","journal-title":"Leuk Res"},{"key":"BFbcj201520_CR28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3324\/haematol.10759","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546\u2013549.","journal-title":"Haematologica"},{"key":"BFbcj201520_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","volume":"73","author":"P Tosi","year":"2004","unstructured":"Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004; 73: 98\u2013103.","journal-title":"Eur J Haematol"},{"key":"BFbcj201520_CR30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bbmt.2010.02.020","volume":"16","author":"P Tosi","year":"2010","unstructured":"Tosi P, Zamagni E, Tacchetti P, Ceccolini M, Perrone G, Brioli A et al. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. Biol Blood Marrow Transplant 2010; 16: 1115\u20131121.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbcj201520_CR31","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","volume":"27","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E et al. VMP (bortezomib, melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009; 27: 6086\u20136093.","journal-title":"J Clin Oncol"},{"key":"BFbcj201520_CR32","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","volume":"28","author":"H Ludwig","year":"2010","unstructured":"Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010; 28: 4635\u20134641.","journal-title":"J Clin Oncol"},{"key":"BFbcj201520_CR33","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1002\/cncr.25139","volume":"116","author":"M Dimopoulos","year":"2010","unstructured":"Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function. Cancer 2010; 116: 3807\u20133814.","journal-title":"Cancer"},{"key":"BFbcj201520_CR34","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1211\/0022357022241","volume":"55","author":"T Eriksson","year":"2003","unstructured":"Eriksson T, Hoglund P, Turesson I, Waage A, Don BR, Vu J et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 2003; 55: 1701\u20131706.","journal-title":"J Pharm Pharmacol"},{"key":"BFbcj201520_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01461.x","volume":"85","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M et al. Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 2010; 85: 1\u20135.","journal-title":"Eur J Haematol"},{"key":"BFbcj201520_CR36","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1124\/jpet.108.142604","volume":"327","author":"R Sarkozi","year":"2008","unstructured":"Sarkozi R, Perco P, Hochegger K, Enrich J, Wiesinger M, Pirklbauer M et al. Bortezomib-induced survival signals and genes in human proximal tubular cells. J Pharmacol Exp Ther 2008; 327: 645\u2013656.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFbcj201520_CR37","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1182\/blood-2010-08-302505","volume":"117","author":"WZ Ying","year":"2011","unstructured":"Ying WZ, Wang PX, Aaron KJ, Basnayake K, Sanders PW . Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism. Blood 2011; 117: 1301\u20131307.","journal-title":"Blood"},{"key":"BFbcj201520_CR38","doi-asserted-by":"crossref","unstructured":"Kastritis E, Terpos E, Roussou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Kalapanida D et al. Very early death (&lt;2 months) in myeloma is associated with advanced age, poor performance status and reduced use of novel agents, while early death within 12 months is associated with high risk features of both the disease and the patient. ASH 2013 Annual Meeting 2013, Abstract 3195.","DOI":"10.1182\/blood.V122.21.3195.3195"},{"key":"BFbcj201520_CR39","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2215\/CJN.08531109","volume":"5","author":"JW Pickering","year":"2010","unstructured":"Pickering JW, Endre ZH . Back-calculating baseline creatinine with MDRD misclassifies acute kidney injury in the intensive care unit. Clin J Am Soc Nephrol 2010; 5: 1165\u20131173.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFbcj201520_CR40","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/leu.2012.296","volume":"27","author":"JT Larsen","year":"2013","unstructured":"Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV . Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013; 27: 941\u2013946.","journal-title":"Leukemia"},{"key":"BFbcj201520_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMc1106428","volume":"365","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Larson D, Kyle RA . Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365: 474\u2013475.","journal-title":"N Engl J Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201520","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:57:32Z","timestamp":1672912652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,20]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3]]}},"alternative-id":["BFbcj201520"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2015.20","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,20]]},"assertion":[{"value":"1 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}